Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells

IF 13.6 1区 医学 Q1 ENGINEERING, BIOMEDICAL
Biomaterials Pub Date : 2014-07-01 Epub Date: 2014-04-08 DOI:10.1016/j.biomaterials.2014.03.041
Li Zhao , Yong-Hong Xu , Tsukasa Akasaka , Shigeaki Abe , Naoki Komatsu , Fumio Watari , Xiao Chen
{"title":"Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells","authors":"Li Zhao ,&nbsp;Yong-Hong Xu ,&nbsp;Tsukasa Akasaka ,&nbsp;Shigeaki Abe ,&nbsp;Naoki Komatsu ,&nbsp;Fumio Watari ,&nbsp;Xiao Chen","doi":"10.1016/j.biomaterials.2014.03.041","DOIUrl":null,"url":null,"abstract":"<div><p>A successful targeted drug delivery<span> device for cancer chemotherapy should ideally be able to avoid non-specific uptake by nonmalignant cells, particularly the scavenging monocyte-macrophage system as well as targeting efficacy to bring the drug preferentially into tumor cells. To this purpose, we developed a platform based on detonation nanodiamond<span> (dND) with hyperbranched polyglycerol<span> (PG) coating (dND-PG). dND-PG was first demonstrated to evade non-specific cell uptake, particularly by macrophages (U937). RGD targeting peptide was then conjugated to dND-PG through multistep organic transformations to yield dND-PG-RGD that still evaded macrophage uptake but was preferentially taken up by targeted A549 cancer cells (expressing RGD peptide receptors). dND-PG and dND-PG-RGD showed good aqueous solubility and cytocompatibitlity. Subsequently, the anticancer agent doxorubicin (DOX) was loaded through acid-labile hydrazone linkage to yield dND-PG-DOX and dND-PG-RGD-DOX. Their cellular uptake and cytotoxicity were compared against DOX in A549 cells and U937 macrophages. It was found that dND-PG-DOX uptake was substantially reduced, displaying little toxicity in either type of cells by virtue of PG coating, whereas dND-PG-RGD-DOX exerted selective toxicity to A549 cells over U937 macrophages that are otherwise highly sensitive to DOX. Finally, dND-PG was demonstrated to have little influence on U937 macrophage cell functions, except for a slight increase of TNF-α production in resting U937 macrophages. dND-PG is a promising drug carrier for realization of highly selective drug delivery in tumor cells through specific uptake mechanisms, with minimum uptake in and influence on macrophages.</span></span></span></p></div>","PeriodicalId":254,"journal":{"name":"Biomaterials","volume":"35 20","pages":"Pages 5393-5406"},"PeriodicalIF":13.6000,"publicationDate":"2014-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.biomaterials.2014.03.041","citationCount":"136","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomaterials","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0142961214002889","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/4/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 136

Abstract

A successful targeted drug delivery device for cancer chemotherapy should ideally be able to avoid non-specific uptake by nonmalignant cells, particularly the scavenging monocyte-macrophage system as well as targeting efficacy to bring the drug preferentially into tumor cells. To this purpose, we developed a platform based on detonation nanodiamond (dND) with hyperbranched polyglycerol (PG) coating (dND-PG). dND-PG was first demonstrated to evade non-specific cell uptake, particularly by macrophages (U937). RGD targeting peptide was then conjugated to dND-PG through multistep organic transformations to yield dND-PG-RGD that still evaded macrophage uptake but was preferentially taken up by targeted A549 cancer cells (expressing RGD peptide receptors). dND-PG and dND-PG-RGD showed good aqueous solubility and cytocompatibitlity. Subsequently, the anticancer agent doxorubicin (DOX) was loaded through acid-labile hydrazone linkage to yield dND-PG-DOX and dND-PG-RGD-DOX. Their cellular uptake and cytotoxicity were compared against DOX in A549 cells and U937 macrophages. It was found that dND-PG-DOX uptake was substantially reduced, displaying little toxicity in either type of cells by virtue of PG coating, whereas dND-PG-RGD-DOX exerted selective toxicity to A549 cells over U937 macrophages that are otherwise highly sensitive to DOX. Finally, dND-PG was demonstrated to have little influence on U937 macrophage cell functions, except for a slight increase of TNF-α production in resting U937 macrophages. dND-PG is a promising drug carrier for realization of highly selective drug delivery in tumor cells through specific uptake mechanisms, with minimum uptake in and influence on macrophages.

聚甘油包被纳米金刚石作为巨噬细胞逃避平台的选择性药物递送在癌细胞
理想情况下,一种成功的癌症化疗靶向给药装置应该能够避免非恶性细胞的非特异性摄取,特别是清除单核细胞-巨噬细胞系统,并具有靶向性,使药物优先进入肿瘤细胞。为此,我们开发了一种基于超支化聚甘油(PG)涂层的爆轰纳米金刚石(dND)平台。dND-PG首先被证明可以逃避非特异性细胞摄取,特别是巨噬细胞(U937)。然后通过多步骤有机转化将RGD靶向肽与dND-PG偶联,得到dND-PG-RGD,该dND-PG-RGD仍能逃避巨噬细胞的摄取,但被靶向的A549癌细胞(表达RGD肽受体)优先吸收。dND-PG和dND-PG- rgd具有良好的水溶性和细胞相容性。随后,抗癌药物阿霉素(DOX)通过酸不稳定的腙键负载,生成dND-PG-DOX和dND-PG-RGD-DOX。在A549细胞和U937巨噬细胞中比较它们与DOX的细胞摄取和细胞毒性。研究发现,由于PG包被,dND-PG-DOX的摄取大大减少,在两种类型的细胞中都表现出很小的毒性,而dND-PG-RGD-DOX对A549细胞对U937巨噬细胞具有选择性毒性,而U937巨噬细胞对DOX高度敏感。最后,dND-PG被证明对U937巨噬细胞的功能几乎没有影响,除了在静止的U937巨噬细胞中TNF-α的产生略有增加。dND-PG是一种很有前途的药物载体,可以通过特定的摄取机制在肿瘤细胞中实现高选择性的给药,对巨噬细胞的摄取和影响最小。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomaterials
Biomaterials 工程技术-材料科学:生物材料
CiteScore
26.00
自引率
2.90%
发文量
565
审稿时长
46 days
期刊介绍: Biomaterials is an international journal covering the science and clinical application of biomaterials. A biomaterial is now defined as a substance that has been engineered to take a form which, alone or as part of a complex system, is used to direct, by control of interactions with components of living systems, the course of any therapeutic or diagnostic procedure. It is the aim of the journal to provide a peer-reviewed forum for the publication of original papers and authoritative review and opinion papers dealing with the most important issues facing the use of biomaterials in clinical practice. The scope of the journal covers the wide range of physical, biological and chemical sciences that underpin the design of biomaterials and the clinical disciplines in which they are used. These sciences include polymer synthesis and characterization, drug and gene vector design, the biology of the host response, immunology and toxicology and self assembly at the nanoscale. Clinical applications include the therapies of medical technology and regenerative medicine in all clinical disciplines, and diagnostic systems that reply on innovative contrast and sensing agents. The journal is relevant to areas such as cancer diagnosis and therapy, implantable devices, drug delivery systems, gene vectors, bionanotechnology and tissue engineering.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书